Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Maris

Showing results (101-110 of 458) with videos related to

Pageof 46
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastomaSteven G DuBois, Julia Messina, John M Maris, et al.
Cancer Research|May 14, 2009
Comparison of primary neuroblastoma tumors and derivative early-passage cell lines using genome-wide single nucleotide polymorphism array analysisSamuel L Volchenboum, Cheng Li, Shuli Li, et al.
Oncogene|July 20, 2007
Prevalence and functional consequence of PHOX2B mutations in neuroblastomaE H Raabe, M Laudenslager, C Winter, et al.
Vaccine|June 2, 1998
Comparison of DNA application methods to reduce BRSV shedding in cattleR S Schrijver, J P Langedijk, G M Keil, et al.
Oncogene|August 29, 2007
Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplificationX Liu, P Mazanek, V Dam, et al.
Mabs|February 25, 2016
Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopesYang Feng, Yanping Wang, Zhongyu Zhu, et al.
Molecular Pharmacology|September 27, 2006
The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastomaJun Fang, Quintin J Quinones, Trevor L Holman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 3, 2019
PARP-1-Targeted Auger Emitters Display High-LET Cytotoxic Properties In Vitro but Show Limited Therapeutic Utility in Solid Tumor Models of Human NeuroblastomaHwan Lee, Aladdin Riad, Paul Martorano, et al.
Frontiers in Immunology|April 8, 2020
Immunogenicity and Immune Silence in Human CancerMark Yarmarkovich, Alvin Farrel, Artemio Sison, et al.
Cancer Research|August 12, 1998
Identification of a consistent region of allelic loss on 1p32 in meningiomas: correlation with increased morbidityE P Sulman, J P Dumanski, P S White, et al.
Pageof 46

Showing results (101-110 of 458) with videos related to

Sort By:
Pageof 46
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastomaSteven G DuBois, Julia Messina, John M Maris, et al.
Cancer Research|May 14, 2009
Comparison of primary neuroblastoma tumors and derivative early-passage cell lines using genome-wide single nucleotide polymorphism array analysisSamuel L Volchenboum, Cheng Li, Shuli Li, et al.
Oncogene|July 20, 2007
Prevalence and functional consequence of PHOX2B mutations in neuroblastomaE H Raabe, M Laudenslager, C Winter, et al.
Vaccine|June 2, 1998
Comparison of DNA application methods to reduce BRSV shedding in cattleR S Schrijver, J P Langedijk, G M Keil, et al.
Oncogene|August 29, 2007
Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplificationX Liu, P Mazanek, V Dam, et al.
Mabs|February 25, 2016
Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopesYang Feng, Yanping Wang, Zhongyu Zhu, et al.
Molecular Pharmacology|September 27, 2006
The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastomaJun Fang, Quintin J Quinones, Trevor L Holman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 3, 2019
PARP-1-Targeted Auger Emitters Display High-LET Cytotoxic Properties In Vitro but Show Limited Therapeutic Utility in Solid Tumor Models of Human NeuroblastomaHwan Lee, Aladdin Riad, Paul Martorano, et al.
Frontiers in Immunology|April 8, 2020
Immunogenicity and Immune Silence in Human CancerMark Yarmarkovich, Alvin Farrel, Artemio Sison, et al.
Cancer Research|August 12, 1998
Identification of a consistent region of allelic loss on 1p32 in meningiomas: correlation with increased morbidityE P Sulman, J P Dumanski, P S White, et al.
Pageof 46